News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Category: Press Releases

​​​​​​​Epigenomics AG announces conversion result of the first conversion period of the mandatory convertible bond 2021/2024

DGAP-News: Epigenomics AG / Key word(s): Bond/Miscellaneous20.04.2021 / 15:39 The issuer is solely responsible for the content of this announcement. Epigenomics AG announces conversion result of the first conversion period of the mandatory convertible bond 2021/2024  Berlin (Germany) and San Diego (U.S.A.), April 20, 2021 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the […]

Read more

Study reported in BMC Gastroenterology shows significantly better performance characteristics of Epigenomics’ liver cancer panel compared to the current standard of care for the early detection of HCC

DGAP-News: Epigenomics AG / Key word(s): Study results/Study06.04.2021 / 07:59 The issuer is solely responsible for the content of this announcement. Study reported in BMC Gastroenterology demonstrates significantly better performance characteristics of Epigenomics’ liver cancer panel compared to the current standard of care for the early detection of hepatocellular carcinoma (HCC) in patients with liver […]

Read more

Epigenomics AG Reports Financial Results for Fiscal Year 2020

DGAP-News: Epigenomics AG / Key word(s): Annual Report/Annual Results25.03.2021 / 11:00 The issuer is solely responsible for the content of this announcement. Epigenomics AG Reports Financial Results for Fiscal Year 2020 Berlin (Germany) and San Diego, CA (U.S.A.), March 25, 2021 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the “Company”) today reported financial results (according […]

Read more

Epigenomics AG: Dr. Garces transitions to Company Advisor

DGAP-News: Epigenomics AG / Key word(s): Personnel27.01.2021 / 08:37 The issuer is solely responsible for the content of this announcement. Epigenomics AG: Dr. Garces transitions to Company Advisor Berlin (Germany) and San Diego, CA (USA), January 27, 2021 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY; the “Company”) announces that Dr. Jorge Garces, President […]

Read more

Epigenomics AG Plans to Challenge NCD Decision and Unveils Its Next Generation Liquid Biopsy Test for Colorectal Cancer Screening

DGAP-News: Epigenomics AG / Key word(s): Miscellaneous/Scientific publication21.01.2021 / 10:02 The issuer is solely responsible for the content of this announcement. Epigenomics AG Plans to Challenge NCD Decision and Unveils Its Next Generation Liquid Biopsy Test for Colorectal Cancer Screening Company evaluating all options to challenge CMS’ decision to non-cover the Epi proColon test New […]

Read more

Epigenomics AG reports financial results for the first nine months of 2020

DGAP-News: Epigenomics AG / Key word(s): Quarterly / Interim Statement/9 Month figures12.11.2020 / 08:47 The issuer is solely responsible for the content of this announcement. Epigenomics AG reports financial results for the first nine months of 2020 Berlin (Germany) and San Diego, CA (U.S.A.), November 12, 2020 – Epigenomics AG (FSE: ECX, OTCQX: EPGNY, the […]

Read more